Biopolymer Patents: Who Leads, Where the Gaps Are 2026
- Filing pulled back sharply after the 2017 peak. 804 records that year against 46 in the most recent (still-filling) year, with a documented -44% drop from 732 filings in 2021 to 408 in 2024.
- No single assignee dominates. The leader holds 945 records and the ranked top 5 combine for just 10.0% of all 29,097 records in scope — concentration is shallow even among the ranked leaders.
- Medical use cases outweigh materials-science claims. A61K and A61L together touch roughly half of all records, while core polymer-composition classes (C08L, C08G) sit well behind them.
Filing growth compares 2021 (732 records) with 2024 (408) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 29,097 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks 29,097 published records matching biodegradable polymer, bio-based plastic and biopolymer resin terminology, cross-referenced against material-property language such as crosslink density, particle morphology and polymer blend. The scope runs from 2015 through the 2026-08-31 cut-off, capturing both the compositional chemistry (polyesters, polyhydroxyalkanoates, polylactides) and the downstream applications that consume it, from wound care to implant coatings.
Because the search terms bridge material science and medical-device language, the corpus reads less like a plastics-industry filing set and more like a cross-disciplinary one: sterilisation, implants and drug-release claims sit alongside pure polymer-composition work. That mix matters for anyone scoping freedom-to-operate, since a device claim can block a materials use case that never mentions the device at all.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 29,097 records: the year-by-year filing count, and the IPC subclasses that carry the technical substance of the claims.
Filing trend, 2017–2026
Filings peaked at 804 in 2017 and have declined since; the -44% move from 732 (2021) to 408 (2024) is the last span long enough to read as a real trend. Everything after 2024 is still filling in as publications lag behind filing by roughly 18 months, so the apparent drop into the most recent years should not be read as the field slowing down.
Technology composition by IPC subclass
Medicinal preparations (A61K, 26.2%) and sterilising/disinfecting (A61L, 23.1%) lead the composition, ahead of implants (A61F, 17.4%). Core polymer-composition classes C08L (10.3%) and C08G (5.6%) trail well behind the medical-use classes, meaning most of the claim density in this corpus is about how the material is used, not how it is built.
Shares are the percentage of the 29,097 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Biopolymers & Biodegradable Plastics Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about biopolymers & biodegradable plastics patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaA representative recent filing
US20260109876A1 — Biodegradable polymer blend and use thereof (BASF SE, 2026-04-23)
Claims a biodegradable polymer blend combining a biodegradable aliphatic-aromatic and/or aliphatic polyester with a second polymer selected from polyhydroxyalkanoates, polylactides and polyglycolic acid, plus polycaprolactone, in specified weight-percent ranges.Abstract trimmed to the compositional claim language; see the full filing for dependent claims and processing conditions.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | EP0058481A1 | Continuous release pharmaceutical compositions | 3,125 |
| 2 | US6770070B1 | Lung treatment apparatus and method | 2,416 |
| 3 | US20120248169A1 | Methods for forming tissue thickness compensator arrangements for surgical staplers | 2,162 |
| 4 | US5886026A | Anti-angiogenic compositions and methods of use | 2,020 |
| 5 | US20130256373A1 | Devices and methods for attaching tissue thickness compensating materials to surgical stapling instruments | 2,002 |
| 6 | US20130256380A1 | Layer of material for a surgical end effector | 1,929 |
| 7 | US9386988B2 | Retainer assembly including a tissue thickness compensator | 1,919 |
| 8 | US5716981A | Anti-angiogenic compositions and methods of use | 1,909 |
| 9 | US6596296B1 | Drug releasing biodegradable fiber implant | 1,903 |
| 10 | US9211120B2 | Tissue thickness compensator comprising a plurality of medicaments | 1,892 |
Citation counts accumulate over time, so older records dominate this list by construction — treat them as markers of influence on later filings, not as evidence of current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the ranking, the trend and the IPC composition are read together.
No single owner controls the field
The leading assignee holds 945 records, but the ranked top 5 together account for only 10.0% of all 29,097 records in scope, and the top 10 for 15.4%. That is a shallow concentration curve: strong incumbents exist, but there is no single gatekeeper whose portfolio a new entrant must design entirely around.
Filing has cooled from its 2017 peak
The peak year was 2017 at 804 filings; the last fully comparable span shows a -44% drop from 732 filings in 2021 to 408 in 2024. Years after 2024 are still filling in under the ~18-month publication lag, so they understate real activity and should not be read as a further slide.
Medical-use claims outweigh materials claims
Medicinal preparations (A61K) and sterilising/disinfecting (A61L) each touch roughly a quarter of the corpus, while the core polymer-composition classes C08L and C08G trail at 10.3% and 5.6%. Anyone filing a pure materials-composition claim is filing into a comparatively less crowded corner of this landscape than a device or drug-release claim covering the same polymer.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to biopolymers & biodegradable plastics patent landscape, with the prior art for and against each one.
Who is active, and where the collaboration sits
The ranked leaders are dominated by research institutions and device makers rather than commodity-plastics producers, which shapes where their claims actually sit.
Research institutions anchor the top of the ranking
The leading assignee's 945 records and the presence of major universities and research institutes among the ranked leaders point to a field where academic and translational-research filing carries real weight alongside corporate portfolios.
Even the leaders are filing less right now
Recent-year momentum for the most active tracked assignees runs from roughly -70% to -100% year-on-year, with several logging zero filings in the latest year. Given the publication lag, this reads as an early signal rather than a confirmed pullback.
A tight cluster of repeat co-filers
Ten co-assignee pairs are tracked in this corpus, with the strongest pairing appearing together on 352 records and the next two pairings on 188 and 153. These numbers describe a small, dense collaboration cluster rather than broad cross-industry co-filing.
| Assignee | Recent year | YoY |
|---|---|---|
| Massachusetts Institute of Technology (MIT) | 3 | -70% |
| The Broad Institute, Inc. | 2 | -75% |
| Abbott Cardiovascular Systems Inc. | 0 | — |
| Ethicon, Inc. | 0 | — |
| Johns Hopkins University | 0 | — |
| President and Fellows of Harvard College | 0 | -100% |
| Kimberly-Clark Worldwide, Inc. | 0 | -100% |
| Alkermes Controlled Therapeutics Inc. | 0 | — |
Where to take this next
The ranking and the trend line answer who and how much; they do not answer whether a specific claim is open. That takes a targeted search against the exact composition and processing language in scope.
Check freedom-to-operate on a specific blend
Run the polymer ratios and process steps you plan to claim against the compositional language already active in this corpus, particularly around A61K/A61L overlap with C08L claims.
Search this landscape in EurekaTrack the leaders' next moves
Set a watch on the assignees with the largest ranked portfolios to catch new filings before the ~18-month publication lag clears.
Monitor assignees in EurekaDraft into the under-claimed branches
Use the gaps identified in the IPC composition, particularly the thinner C08G and C08L shares, to scope a first claim with more room to move.
Explore white space in EurekaCommon questions about this landscape
The ranking behind this landscape covers 100 companies and research institutions, with the leading assignee holding 945 records. Concentration is shallow: the top 5 combined account for only 10.0% of all 29,097 records in scope, and the top 10 for 15.4%, so no single organisation controls the field the way a leader sometimes does in more consolidated technologies. Universities and translational-research institutes feature prominently alongside device and materials companies, which reflects how much of this corpus sits at the intersection of polymer chemistry and medical application.
Filings peaked in 2017 at 804 records and have declined since, with a documented drop of 44% from 732 filings in 2021 to 408 in 2024 — the last three-year span that can be treated as complete. Years after 2024 show much lower counts, but that is largely an artefact of the roughly 18-month lag between filing and publication rather than a confirmed slowdown. Anyone reading the most recent year or two as a trend should wait for those years to finish filling in before drawing conclusions.
The corpus splits across medical-use classes and core materials classes. A61K (medicinal preparations) and A61L (sterilising and disinfecting) each cover roughly a quarter of the 29,097 records, and A61F (implants and prostheses) covers 17.4%. The classes closer to pure materials science — C08L (polymer compositions) at 10.3% and C08G (condensation polymers) at 5.6% — carry meaningfully less claim density, which is useful to know when deciding whether a composition claim is landing in a crowded or an open part of the space.
The IPC composition suggests the materials-science side of this field — condensation polymer processing, crosslink density control and particle morphology in blends — is claimed far less densely than the medical-device and drug-release side. That does not mean these branches are unclaimed, but the filing density is lower relative to A61K and A61L, so a composition- or processing-focused claim that avoids medical-use language may face a thinner prior-art landscape. Confirming this for a specific blend still requires a targeted search rather than relying on the aggregate IPC shares alone.
Patent families are the fairer unit than raw document counts because they neutralise the effect of aggressive continuation filing and multi-jurisdiction duplication of the same invention. In this dataset the assignee ranking is counted in records against a total of 29,097 patent families, so the ranking and the record totals are on a comparable basis. When comparing this landscape to another dataset, always check whether the other source is counting families, applications or granted patents before comparing shares directly.
Research Biopolymers & Biodegradable Plastics Patent Landscape in depth with Eureka
Go past this page: query the whole biopolymers & biodegradable plastics patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.